secwatch.observer — SEC 8-K summary
======================================

Issuer:     CorMedix Inc. (CRMD)
CIK:        0001410098
Form:       8-K
Filed at:   2023-05-16T23:59:59+00:00
Accession:  0001213900-23-040128
Event type: regulatory
Sentiment:  positive
Materiality: 0.75
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

CorMedix resubmits DefenCath NDA to FDA for hemodialysis catheter infection prevention
--------------------------------------------------------------------------------

- NDA for DefenCath resubmitted to FDA as of May 15, 2023; agency acknowledged receipt for processing.
- CEO Joe Todisco said resubmission follows prior earnings call; company aims for potential approval in 2023.
- DefenCath is designed to reduce bloodstream infections in hemodialysis patients using central venous catheters.
- Resubmission addresses prior FDA feedback; no specific timeline for review decision provided.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1410098/000121390023040128/0001213900-23-040128-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1410098/000121390023040128/ea178697-8k_cormedix.htm
  HTML page:      https://secwatch.observer/filing/0001213900-23-040128

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer